Metahexamide
From Wikipedia, the free encyclopedia
| Names | |
|---|---|
| Preferred IUPAC name
3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide | |
| Identifiers | |
| |
3D model (JSmol)
|
|
| ChEMBL |
|
| ChemSpider |
|
| ECHA InfoCard | 100.008.434 Edit this at Wikidata |
| KEGG |
|
PubChem CID
|
|
| UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C14H21N3O3S | |
| Molar mass | 311.4 g/mol |
| Pharmacology | |
| A10BB10 (WHO ) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Chemical compound
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
References
[edit ]- ^ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. Bibcode:1959NYASA..82..614M. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
Stub icon
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.